Oct 17, 2008 by Brian Orelli, PhDGilead Sciences Killed ItThe virus-killer killed analysts' expectations, as well.
Oct 17, 2008 by Brian Orelli, PhDShareholders Slap StrykerA little earnings miss sends the medical technology company down.
Oct 16, 2008 by Brian Orelli, PhDFoolish Forecast: Robots on the CheapViews you can use to get clues on tomorrow's news.
Oct 15, 2008 by Brian Orelli, PhDAbbott's Stents Aren't (That) ImportantFocus on what really matters.
Oct 14, 2008 by Brian Orelli, PhDJohnson & Johnson, Heal ThyselfWhen your brother falls, you've got to pick up the pace.
Oct 13, 2008 by Brian Orelli, PhDToo Little Too Late for Boston ScientificThe company gets new stent approved, but it should have happened earlier.
Oct 13, 2008 by Brian Orelli, PhDFoolish Forecast: J&J's Diversity CountsViews you can use to get clues on tomorrow's news
Oct 10, 2008 by Brian Orelli, PhDShareholders Swoon at Sight of BloodOmrix Biopharmaceuticals has this matter covered.
Oct 9, 2008 by Brian Orelli, PhDWhen Science, Marketing, and Investing CollideHow a pharmaceutical tries to sell more drugs can provide clues about its management.
Oct 9, 2008 by Brian Orelli, PhDIs Monsanto Back?Investors are giddy about Monsanto again. Should they be?
Oct 8, 2008 by Brian Orelli, PhDPfizer Rearranges the Deck ChairsA reorganization without any job cuts isn't going to make the Lipitor problem go away.
Oct 8, 2008 by Brian Orelli, PhDLilly Gets Off EasyThe company settles marketing issues over Zyprexa with 32 states.
Oct 7, 2008 by Brian Orelli, PhDResults IMPACT Volatility at DendreonDendreon almost hits both a 52-week high and a 52-week low on the day it releases results.
Oct 7, 2008 by Brian Orelli, PhDEli Lilly's Risky GambleIt's desperate, and the high acquisition price of ImClone shows it.
Oct 7, 2008 by Brian Orelli, PhDWill a Better Drug Sell Better?Positive trial data isn't enough to significantly boost Johnson & Johnson's Remicade.
Oct 6, 2008 by Brian Orelli, PhDCardinal Atones for Its SinsThe drugmaker gets its licenses to distribute controlled substances reinstated.
Oct 6, 2008 by Brian Orelli, PhDBailout Brings a Little Credit for ResearchAs part of the big bill, Congress renews the research and development tax credit.
Oct 3, 2008 by Brian Orelli, PhDMerck Can't Fight the MunchiesThe pharma gives up on its anti-obesity drug.
Oct 3, 2008 by Brian Orelli, PhDAmgen Draws Blood in Anemia-Drug WarThe pharmaceutical fights off rival Roche.
